Glycerolipid Lipases
Products for Glycerolipid Lipases
- Cat.No. Product Name Information
-
GC45257
(+)-AS 115
KIAA1363 is a 2-acetyl monoacylglyceryl ether (MAGE) hydrolase that is upregulated in aggressive cancers from various tissues.
-
GC41718
(R)-KT109
(R)-KT109 is the (R) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109.
-
GC41738
(S)-KT109
(S)-KT109 is the (S) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109.
-
GC49044
Benastatin C
A bacterial metabolite with diverse biological activities
-
GC47060
CAY10762
An inhibitor of MAGL
-
GC45995
DO264
An ABHD12 inhibitor
-
GC60211
JNJ-42226314
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor.
-
GC43935
JW 618
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors.
-
GC44014
KT109
In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position.
-
GC45492
KT172
-
GC45491
KT172
-
GC44049
LEI-106
In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position.
-
GC41185
MAGL Inhibitor Compound 23
MAGL Inhibitor Compound 23 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL Inhibitor Compound 23 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL Inhibitor Compound 23 blocks MAGL in cell-based as well as in vivo assays.
-
GC44481
O-7460
In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position.
-
GC49236
Orlistat-d3
(-)-Tetrahydrolipstatin-d3
An internal standard for the quantification of orlistat